Lohith Gowda

Abstract Ciltacabtagene autoleucel (cilta-cel), an anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy, was approved in 2022 for heavily pretreated relapsed/refractory multiple myeloma (RRMM). This study evaluates the safety and efficacy of cilta-cel in RRMM patients reported to the Center for International Blood and Marrow Transplant Research registry between March 2022 and December 2023 who met commercial release specifications.

Introduction This blog post is your guide to seamlessly exposing Fiori apps from your on-premise system within the dynamic environment of SAP Build Work Zone, leveraging the power of SAP Business Technology Platform (BTP). SAP Build Work Zone: SAP Build Work Zone enables business users to create and customize business sites intuitively. By providing secure, centralized access to SAP and non-SAP applications, processes, and data on various devices, it enhances productivity and engagement.

Original Investigation Trends in Late Mortality and Life Expectancy After Allogeneic Blood or Marrow Transplantation Smita Bhatia, MD, MPH; Chen Dai, MS; Wendy Landier, PhD; Lindsey Hageman, MPH; Jessica Wu, MPH; Elizabeth Schlichting, MBA; Arianna Siler, BA; Erin Funk, BA; Jessica Hicks, BS; Alysia Bosworth, BA; Hok Sreng Te,  BA; Liton Francisco, BS; Ravi Bhatia, MD; Donna Salzman, MD; Frederick D. Goldman, MD; Stephen J. Forman, MD; Daniel J. Weisdorf, MD; F.